They found that 64 percent of lung adenocarcinoma patients had at least one
oncogenic driver gene.
As new
oncogenic driver genes are identified, the testing process becomes less efficient because more genes need to be analyzed in limited amounts of tumor tissue.
Not exact matches
Notably, MYH9, PPP1R12B and TP53BP2 were also frequently aberrated in human ILC, highlighting these
genes as
drivers of a novel
oncogenic pathway underlying ILC development.
We have hundreds of these
gene pairs in hand and are now developing drugs targeting the synthetic lethal partner of major
oncogenic drivers.